Investment objective & strategy
As of May 29, 2025 · prospectusObjective. The Fund seeks to provide long-term capital appreciation.
Strategy. Under normal circumstances, the Fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. The Fund may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The Funds advisor strives for a balanced representation of the health care field, searching for the best values in the various subsectors of the industry. The Fund may invest up to 50% of its assets in foreign stocks. Under normal circumstances, the Fund invests at least 80% of its assets in the stocks of companies principally engaged in the development, production, or distribution of products and services related to the health care industry. These companies include, among others, pharmaceutical firms, medical supply companies, and businesses that operate hospitals and other health care facilities. The Fund may also consider companies engaged in medical, diagnostic, biochemical, and other research and development activities. The Funds advisor strives for a balanced representation of the health care field, searching for the best values in the various subsectors of the industry. The Fund may invest up to 50% of its assets in foreign stocks.
Top holdings
As of Jan. 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| LILLY ELI and CO | — | $3.83B | 9.76% |
| ASTRAZENECA PLC | — | $2.16B | 5.49% |
| MERCK & CO | — | $2.00B | 5.09% |
| UNITEDHEALTH GRP | — | $1.37B | 3.49% |
| JOHNSON&JOHNSON | — | $1.22B | 3.11% |
| EDWARDS LIFESCIENCES CORP | — | $1.22B | 3.10% |
| GSK PLC | — | $1.17B | 2.98% |
| DANAHER CORP | — | $1.06B | 2.70% |
| ABBOTT LABS | — | $1.01B | 2.58% |
| INTUITIVE SURGICAL INC | — | $980.64M | 2.50% |
Portfolio moves
Oct 31, 2025 → Jan 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| THE HARTFORD HEALTHCARE FUND · HGHAX, HGHCX, HGHYX, HGHIX, HGHRX, HGHSX, HGHTX, HGHFX, HGHVX | 68% | 0.94% |
| HARTFORD HEALTHCARE HLS FUND · HIAHX, HBGHX | 68% | 0.93% |
| JPMorgan Healthcare Leaders ETF · JDOC | 51% | 0.65% |
Advisers
| Firm | Role |
|---|---|
| Wellington Management Company LLP | Adviser |
Footnotes
- Expense ratio as of May 29, 2025, from the fund's prospectus.
- Net assets and holdings count as of January 31, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.